Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Treatment Patterns and Outcomes in Postmenopausal, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Metastatic Breast Cancer Patients Treated With Palbociclib Plus an Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04460898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04460898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Treatment Patterns and Outcomes in Postmenopausal, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Metastatic Breast Cancer Patients Treated With Palbociclib Plus an Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
January 4, 2019
Completion date
June 24, 2019
Enrollment
195 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer